A Randomized, Double-blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Lubiprostone in Adult Subjects With Mixed or Unsubtyped Irritable Bowel Syndrome (IBS-M/IBS-U)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Lubiprostone (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors Sucampo Pharmaceuticals
- 22 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 May 2017.
- 06 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 12 Sep 2015 New trial record